1,3,5-Trihydroxy-4-prenylxanthone is a relatively potent inhibitor of phosphodiesteRase type 5 (PDE5), with an IC50 value of 3.0 μM; it shows in vitro inhibitory activity against acetylcholinesteRase (AChE) and butyrylcholinesteRase (BChE), with IC50 values of 56.3plusmn;0.4 and 46.0plusmn;0.3 M, respectively. 1,3,5-Trihydroxy-4-prenylxanthone inhibits LPS-induced NF-Κb and AP-1 activations by interfering with the posttranslational modifiCATion (phosphorylation and/or ubiquitinylation) of IRAK-1 in the cell membrane to impede TAK1-mediated activation of IKK and MAPKs signal transduction.

1,3,5-Trihydroxy-4-prenylxanthone is a relatively potent inhibitor of phosphodiesterase type 5 (PDE5), with an IC50 value of 3.0 μM; it shows in vitro inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 56.3plusmn;0.4 and 46.0plusmn;0.3 M, respectively. 1,3,5-Trihydroxy-4-prenylxanthone inhibits LPS-induced NF-κB and AP-1 activations by interfering with the posttranslational modification (phosphorylation and/or ubiquitinylation) of IRAK-1 in the cell membrane to impede TAK1-mediated activation of IKK and MAPKs signal transduction.

53377-61-0

C18H16O5

312.32

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years